Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead Sciences

Showing 8 posts of 23 posts found.

msd

MSD’s Zepatier approval could spell end of Gilead’s Hep C dominance, says analyst

February 10, 2016
Sales and Marketing AbbVie, Drug pricing, Gilead Sciences, MSD, Solvadi, Viekira Pak, harvoni, hepatitis C

The introduction of MSDs’ recently FDA-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market …

News
john_milligan_gilead_sciences

Gilead Sciences names John Milligan new CEO

January 29, 2016
Medical Communications, Sales and Marketing Gilead Sciences, John Martin, John Milligan

Gilead Sciences has announced that chairman and chief executive John Martin is to step down after 20 years at the …

Appointment
Gilead sign

Gilead steps in to rescue Galapagos RA drug

December 18, 2015
Sales and Marketing AbbVie, Gilead, Gilead Sciences, filgotinib, inflammation, inflammatory diseases, rheumatoid arthritis

Gilead Sciences is to pay $725million for the rights to filgotinib, a JAK1-selective inhibitor for rheumatoid arthritis and other inflammatory …

News
Sovaldi bottle

Gilead’s Sovaldi wins Drug Discovery of the Year Award

December 16, 2015
Research and Development British Pharmacological Society, Gilead, Gilead Sciences, hepatitis C, sofosbuvir, sovaldi

Gilead Science’s hepatitis C treatment Sovaldi has been awarded the British Pharmacological Society’s prestigious Drug Discovery of the Year 2016. …

News
Gilead image

EU approval for Gilead’s HIV combo Genvoya

December 1, 2015
Manufacturing and Production, Sales and Marketing European Commission, Genvoya, Gilead, Gilead Sciences, HIV, TDF, World Aids Day, european union, taf

Gilead Sciences has won marketing authorisation from the European Commission (EC) for the once-daily single tablet regimen Genvoya as an …

News
Gilead image

FDA expands Gilead’s Harvoni indications for Hep C

November 13, 2015
Sales and Marketing Gilead, Gilead Sciences, harvoni, ledipasvir-sofosbuvir

Gilead’s Harvoni has been approved by the FDA for expanded use in patients with genotypes 4, 5 and 6 chronic …

News
gilead-sciences

Gilead presents Phase III results for Genvoya in HIV

October 22, 2015
Medical Communications, Research and Development Genvoya, Gilead Sciences, HIV

Gilead Sciences has today announced 96-week results from two Phase III studies evaluating its investigational once-daily single tablet regimen (STR), …

News
gilead-sciences

NICE approves first in new class of leukaemia drugs

September 24, 2015
Cancer Drugs Fund, Gilead Sciences, NHS, NICE, idelalisib, leukaemia, zydelig

NICE has issued final draft guidance which recommends that Gilead’s Zydelig should be made available on the NHS for some …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026